七国癌症生存、死亡与发病趋势进展(1995-2014):ICBP SURVMARK-2人群研究
该纵向人群研究纳入七国21个辖区1995-2014年诊断的七类癌症患者数据,计算1年与5年年龄标准化净生存率并映射发病与死亡变化。几乎全部癌种的1年与5年净生存率在各国均上升,2010-14年澳大利亚、加拿大、挪威总体高于新西兰、丹麦、爱尔兰与英国;七类癌中四类显示癌症控制进展,国际差异持续存在。
要点
- 1995-2014年七国几乎所有癌种1年与5年净生存率均上升。
- 2010-14年澳大利亚、加拿大、挪威生存率总体高于新西兰、丹麦、爱尔兰与英国。
- 胃癌、结肠癌、肺癌(男性)与卵巢癌显示癌症控制进展。
核心结论
- 七类癌中四类(胃、结肠、肺癌(男性)、卵巢)在发病、死亡与生存联合评估中显示癌症控制进展。
- 高收入国家癌症生存持续上升,但国际差异持续存在。
研究设计与样本
- 覆盖食管、胃、结肠、直肠、胰腺、肺与卵巢七类癌,计算1年与5年年龄标准化净生存率。
主要发现
- 1995-2014年几乎所有癌种的1年与5年净生存率在各国均上升,丹麦、爱尔兰与英国直肠癌5年生存率提升超过13个百分点。
- 2010-14年澳大利亚、加拿大与挪威生存率总体高于新西兰、丹麦、爱尔兰与英国。
- 诊断时小于75岁患者生存改善大于75岁及以上患者,食管、胃、胰腺与肺癌等预后差癌种改善明显。
关键数值与推荐
- 5年直肠癌生存率在丹麦、爱尔兰与英国提升超过13个百分点(1995-2014年)。
临床怎么用
- 联合评估发病、死亡与生存趋势可用于判断癌症控制进展,而非仅看生存率。
- 诊断时分期、及时获得有效治疗与合并症程度可能是患者结局的主要决定因素。
局限性
- 有效比较需登记实践、分类与编码差异最小化。
- 诊断时分期、及时治疗与合并症影响尚需未来研究评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Population-based cancer survival estimates provide valuable insights into the effectiveness of cancer services and can reflect the prospects of cure. As part of the second phase of the International Cancer Benchmarking Partnership (ICBP), the Cancer Survival in High-Income Countries (SURVMARK-2) project aims to provide a comprehensive overview of cancer survival across seven high-income countries and a comparative assessment of corresponding incidence and mortality trends. METHODS: In this longitudinal, population-based study, we collected patient-level data on 3·9 million patients with cancer from population-based cancer registries in 21 jurisdictions in seven countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway, and the UK) for seven sites of cancer (oesophagus, stomach, colon, rectum, pancreas, lung, and ovary) diagnosed between 1995 and 2014, and followed up until Dec 31, 2015. We calculated age-standardised net survival at 1 year and 5 years after diagnosis by site, age group, and period of diagnosis. We mapped changes in incidence and mortality to changes in survival to assess progress in cancer control. FINDINGS: In 19 eligible jurisdictions, 3 764 543 cases of cancer were eligible for inclusion in the study. In the 19 included jurisdictions, over 1995-2014, 1-year and 5-year net survival increased in each country across almost all cancer types, with, for example, 5-year rectal cancer survival increasing more than 13 percentage points in Denmark, Ireland, and the UK. For 2010-14, survival was generally higher in Australia, Canada, and Norway than in New Zealand, Denmark, Ireland, and the UK. Over the study period, larger survival improvements were observed for patients younger than 75 years at diagnosis than those aged 75 years and older, and notably for cancers with a poor prognosis (ie, oesophagus, stomach, pancreas, and lung). Progress in cancer control (ie, increased survival, decreased mortality and incidence) over the study period was evident for stomach, colon, lung (in males), and ovarian cancer. INTERPRETATION: The joint evaluation of trends in incidence, mortality, and survival indicated progress in four of the seven studied cancers. Cancer survival continues to increase across high-income countries; however, international disparities persist. While truly valid comparisons require differences in registration practice, classification, and coding to be minimal, stage of disease at diagnosis, timely access to effective treatment, and the extent of comorbidity are likely the main determinants of patient outcomes. Future studies are needed to assess the impact of these factors to further our understanding of international disparities in cancer survival. FUNDING: Canadian Partnership Against Cancer; Cancer Council Victoria; Cancer Institute New South Wales; Cancer Research UK; Danish Cancer Society; National Cancer Registry Ireland; The Cancer Society of New Zealand; National Health Service England; Norwegian Cancer Society; Public Health Agency Northern Ireland, on behalf of the Northern Ireland Cancer Registry; The Scottish Government; Western Australia Department of Health; and Wales Cancer Network.
引用
- Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019. PMID: 31521509. doi:10.1016/S1470-2045(19)30456-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。